TransMolecular Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting

CAMBRIDGE, Mass.--(Business Wire)--
TransMolecular, Inc. today announced new data highlighting the anti-angiogenic
and tumor-targeting properties of TM601 in a poster presentation and in a
published abstract at the 45th Annual Meeting of the American Society of
Clinical Oncology (ASCO). In a clinical study of patients with recurrent
glioblastoma, the first cohort of patients analyzed showed correlative
reductions in vascular perfusion and prolongation of progression-free survival.
A separate clinical study, utilizing radiolabeled TM601, demonstrated highly
specific tumor uptake of intravenously delivered 131I-TM601 in several different
primary and metastatic tumor types, including glioma, metastatic melanoma,
pancreatic cancer, prostate cancer and non-small cell lung cancer. Of note,
selective tumor-specific uptake of 131I-TM601 was observed in six cases of
melanoma with metastases in the brain, demonstrating that 131I-TM601 localized
to metastatic tumors across the blood-brain barrier. TM601 is a novel, wholly
synthetic peptide, found to have robust anti-angiogenic activity in neovascular
diseases, including cancer and ophthalmic disease.

Alison O`Neill, M.D., Vice President, Medical Affairs of TransMolecular, said,
"Both of these studies provide important confirmatory information about our
cancer program and the unique peptide, TM601, on which it is based. The data on
unlabeled TM601 reveals that vascular perfusion is potentially a biomarker for
TM601 treatment response, and the activity seen in this study is consistent with
the unique anti-angiogenic activity of the compound, which we reported at a
recent medical meeting. The published abstract provides important
proof-of-principle for the successful intravenous delivery of 131I-TM601 to
several different tumor types throughout the body. In addition, the data provide
additional validation for our approach of using the TM601 tumor-targeting
platform as a powerful tool to deliver payloads of relevant cancer therapeutics
to malignant tumors scattered throughout the body, including within the central
nervous system."

"These two studies are part of TransMolecular`s extensive clinical development
strategy for the TM601 platform, which has included numerous clinical studies
enrolling many patients," said Robert Radie, President and Chief Executive
Officer of TransMolecular. "We therefore believe that the positive results we
have seen so far from these studies provide important information on the
anti-cancer activity of the peptide and its broad applicability across many
tumor types."

Poster Presentation #2041 Details

Six patients with recurrent glioblastoma have been enrolled in the clinical
study of intravenous unlabeled TM601, which is utilizing perfusion MRI to
monitor the anti-angiogenic effects of TM601. Initially, all patients received a
test dose of 10mCi 131I-TM601 to demonstrate tumor-specific uptake prior to
receiving intravenous treatment doses of 0.04mg/kg unlabeled TM601 weekly for
three weeks in a four-week cycle; cyclic treatment continued until tumor
progression. On week four of each cycle, patients were evaluated with
conventional and dynamic susceptibility contrast MRI to assess perfusion.
Results demonstrate that two of six patients in the first dosing cohort have
exhibited a greater than 25% reduction in relative cerebral blood flow and/or
relative cerebral blood volume, compared to baseline. Importantly, both patients
that demonstrated these improvements in perfusion MRI have also experienced
extended response to TM601.

Published Abstract #e14507 Details

The abstract details imaging and safety data from a clinical study of
intravenous 131I-TM601 in patients with metastatic solid tumors of a variety of
histologic types. Initially, all patients received an intravenous imaging test
dose of 10mCi/0.2mg 131I-TM601 to demonstrate tumor localization. Patients that
did not demonstrate localization received a second imaging test dose of 20
mCi/0.4mg 131I-TM601. Only patients showing tumor localization without toxicity
continued in the study and received an intravenous treatment dose of 30
mCi/0.6mg 131I-TM601.

According to the abstract, 44 patients received intravenous doses of 131I-TM601
without dose-limiting toxicity, with 31 of 44 (70%) demonstrating tumor-specific
uptake on follow-up gamma camera or SPECT imaging. Tumor-specific uptake was
observed in 7/8 malignant glioma patients, 7/7 metastatic melanoma patients, 3/4
non-small cell lung cancer patients, 6/7 colon cancer patients, 2/3 pancreatic
cancer patients, 2/2 prostate cancer patients, 1/4 breast cancer patients, and
one evaluable patient each with transitional cell carcinoma, pleomorphic
xanthoastrocytoma and metastatic paraganglioma. Importantly, all patients with
melanoma metastatic to the brain demonstrated tumor-specific uptake of
131I-TM601, which confirms prior studies that have shown that 131I-TM601 can
localize to tumors across the blood-brain barrier.

About TM601

TM601 is a novel, wholly synthetic peptide found to have robust anti-angiogenic
activity in neovascular diseases, including cancer and ophthalmic disease.

For oncology applications, TM601 is highly specific and selective in targeting
both primary tumors and metastases in the periphery and in the central nervous
system. TM601 has the unique properties of highly specific tumor cell binding,
uptake and internalization. Clinical studies confirm that TM601 targets and
binds to a receptor expressed on a wide range of tumor cells, but not on normal,
healthy cells. TransMolecular is expanding the TM601 tumor-targeting platform to
deliver a range of therapeutic agents, including novel and currently used
chemotherapeutic agents, as well as RNAi molecules, to tumor cells.

Most recently, the effects of TM601 on the neovasculature were validated in
animal models of ophthalmic disease, including wet age-related macular
degeneration (AMD).

About TransMolecular, Inc.

TransMolecular, Inc. is committed to discovering and developing novel
therapeutic products that help patients combat cancer and neovascular diseases.
TransMolecular`s product pipeline is based on the TM601 platform, a novel
synthetically derived polypeptide, which has both highly specific tumor binding
properties and anti-angiogenic therapeutic properties. More information can be
found at www.transmolecular.com.

This press release contains forward-looking statements. The Company wishes to
caution the reader of this press release that actual results may differ from
those discussed in the forward-looking statements and may be adversely affected
by, among other things, risks associated with litigation, clinical trials, the
regulatory approval process, reimbursement policies, commercialization of new
technologies, intellectual property, and other factors.

TransMolecular:
Robert Radie, 617-995-3050 x 303
President and CEO
or
Media:
MacDougall Biomedical Communications
Jennifer Conrad, 781-235-3060
jconrad@macbiocom.com

Copyright Business Wire 2009